title: Long-term administration of a commercial porcine reproductive and respiratory syndrome virus (PRRSV)-inactivated vaccine in PRRSV-endemically infected sows.
abstract: The purpose of this study was to investigate the safety and efficacy of a commercial European porcine reproductive and respiratory syndrome virus (PRRSV)-inactivated vaccine after 18-month use in gilts/sows at a farm with high seroprevalence. In a farrow-to-finish farm with 1100 sows, all sows and gilts were systematically vaccinated with the PRRS-inactivated PROGRESSIS vaccine for a period of 18 months. Farm's reproductive and litter characteristics were longitudinally recorded for this period and historically compared with those of the year prior to vaccination. Serology, employing immunoperoxidase monolayer assay, had confirmed a high prevalence of PRRS-specific antibodies in most age groups within the farm prior to vaccination. Seroprevalence during the experiment ranged between 0% and 100% in weaners and growers, but remained at stable high levels (> 93%) in finishing pigs and gilts throughout all 2-year period of serology measurements. No local or systemic vaccine side effects were noted throughout the trial period. Vaccinations had resulted over time in a significant improvement of sow reproductive performance (e.g. reduction of premature farrowings, abortions and increase of farrowing rate) and litter characteristics (e.g. increase of the number of live born and weaned pigs and decrease of stillborn, mummified, weak and splay-legged piglets). It has also been observed that the higher the degree of immunization of a sow, the better the improvement of her reproductive parameters. Sows after vaccination have shown improved characteristics compared to homoparous sows prior to the application of vaccinations in the farm.
authors.affiliation: Clinic of Productive Animal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Macedonia, Greece.
authors.forename: V G
authors.initials: VG
authors.lastname: Papatsiros
authors.forename: C
authors.initials: C
authors.lastname: Alexopoulos
authors.forename: S K
authors.initials: SK
authors.lastname: Kritas
authors.forename: G
authors.initials: G
authors.lastname: Koptopoulos
authors.forename: H J
authors.initials: HJ
authors.lastname: Nauwynck
authors.forename: M B
authors.initials: MB
authors.lastname: Pensaert
authors.forename: S C
authors.initials: SC
authors.lastname: Kyriakis
mesh_terms: D000034:Abortion, Veterinary; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D008098:Litter Size; D019318:Porcine Reproductive and Respiratory Syndrome / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D019316:Porcine respiratory and reproductive syndrome virus / Q000276:immunology*; D011247:Pregnancy; D011897:Random Allocation; D012098:Reproduction / Q000502:physiology*; D016036:Seroepidemiologic Studies; D013552:Swine; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014886:Weaning
chemical_list: D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines